Meiling LiScientist at Hoffmann-La Roche
Dr. Meiling Li is a member of the RNA Therapeutics Group at F. Hoffmann-La Roche, Basel, Switzerland. Her current research area is on backbone-modified Locked Nucleic Acids with a particular focus on stereodefined phosphorothioates and phosphorodithioates. Dr. Li received her PhD from University of Oxford (UK) in organic chemistry. She then moved to the ETH Zurich as a postdoctoral fellow, joining the group of Prof. Jonathan Hall, where she developed the stereodefined synthesis of MOE-modified antisense oligonucleotides. In her current role she supports various drug discovery programs focusing on the lead optimization of LNA-based antisense oligonucleotides.